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Abstract
Periodontal disease is an infectious and inflammatory process of the supporting structures of the teeth, the result of the interaction between infection by pathogenic 
bacteria and the host’s immune response. In periodontitis patients, compared to those with good periodontal health, there appears to be an increased risk of some 
systemic diseases in general and coronary artery disease in particular. It is not evident that this association is causal and, therefore, could be considered an independent 
factor for the development of cardiovascular diseases.
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Introduction
Effects of topical doxycycline 
Almost all microorganisms related to periodontal disease are 
sensitive to tetracyclines, because of this we use doxycycline, which 
is a second-generation semi-synthetic derivative, as an adjunct to 
periodontal treatment [1-4].
The literature shows heterogeneous results, thus, there are studies 
that show the effect of tetracyclines, especially second-generation ones, 
on the improvement of both clinical and biochemical parameters [5-
8]. According to this line of thinking, there are studies that use slow 
release microspheres of minocycline or fibers with tetracycline [9-10]. 
Therefore, there are important differences in the short-term, but not 
in the long-term, and others that do not show differences regarding to 
scraping and root planning [11-14]. The heterogeneity of the results 
could be explained because of the short-term execution of the studies, 
almost all of them are considered three months. It has been suggested, 
in some studies that can obtain results even with statistical significance, 
that it would require a longer-term monitoring study execution, 
between 6 and 12 months or the repetition of doses throughout the 
treatment to optimize the response [15-16].
Inflammatory markers in periodontal disease 
The existence at the moment of an extensive bibliography about 
periodontal disease, as a potential risk factor for various organs and 
systems, has given rise to some authors such as Steven Offenbacher in 
1996, who proposed a new discipline, the “Periodontal Medicine”. This 
sale refers to the specialty that aims to study the relationship between 
periodontal pathologies and systemic diseases [17]. Saikku et al. [18] 
published the first articles, in which the link between bacterial infections 
and coronary heart disease is highlighted; also in 1995 Patel et al. [19] 
links chronic viral infections by Cytomegalovirus and Herpesvirus. 
Periodontal disease and arteriosclerotic processes appear related in the 
works of Mattila et al. [20], Beck et al. [21] and in 2007 by Gostman et 
al. [22], which indicate that periodontitis produces bacteremia, which 
is manifested in an increase in proinflammatory markers, TNFα, IL-1, 
IL6 and hsCRP. Buhlin et al. [23], Gani et al. [24] and in 2010 Nakajima 
et al. [25] which refers to periodontitis is associated with limited levels 
of markers such as hsCRP and IL-6. Yoshii et al. [26] indicate that 
these levels do not precede periodontitis, but rise with it. D ́Aiuto et al. 
[27], Behle et al. [28], observe a significant reduction in inflammatory 
markers after periodontal treatment; even of PAI-1, VCAM-1 and 
MMP-9. On the other hand, in 2001 Ridker et al. [29] study hsCRP as a 
predictor of cardiovascular risk and Tonetti et al. [30] demonstrates an 
improvement in endothelial dysfunction after periodontal treatment. 
All these studies and investigations can be interpreted as a link between 
periodontal disease and arteriosclerosis cardiovascular pathology.
Material and methods
Study population
A cross section of patients diagnosed with periodontitis was 
taken so as to be studied in a clinical trial with a therapeutic objective, 
which should allow after three months, evidence of the effectiveness of 
periodontal treatment. Topical doxycycline was applied as an adjuvant 
in order to optimize the results and achieve the objectives set; the work 
is structured in three parts.
The first part will have analytical purposes and will consist of a 
periodontal study, which will be performed at the time of diagnosis, 
as well as a blood test to determine the serum level of hsCRP and 
fibrinogen. The second part will have an interventionist character, in 
which all patients will undergo a non-surgical periodontal treatment, 
topical doxycycline will be applied in lesions ≥ 5 mm.
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The third part will carry out a new periodontal study three months 
after having carried out the treatment, and the blood level of hsCRP and 
fibrinogen will be determined again.
Selection criteria
Inclusion criteria: patients with a Probing Depth > 3 mm in at least 
one probing site in two or more teeth, and/or loss of interproximal 
clinical insertion ≥ 3 mm as criteria to diagnose the process as chronic 
periodontitis according to criteria of the AAP-EFP 2018 [31].
Exclusion criteria were: less than fourteen teeth, aggressive 
periodontitis, infectious or other inflammatory diseases, periodontal 
treatment in the last 6 months or antibiotics in the last 3 months, 
treatment with systemic anti-inflammatory drugs (NSAIDs), pregnancy 
or lactation, secondary obesity (hypothyroidism, Cushing’s syndrome), 
or any medical condition requiring antibiotic treatment before the 
dental intervention
Results and discussion
Previous studies have also shown improvements in proinflammatory 
markers, IL-6 and αTNF in patients to whom topical doxycyclin is 
applied [32-33], which consequently shows inflammation modulating 
actions in its local application, as previously observed after systemic 
administration at subtherapeutic doses [34-36].
The biochemical reevaluation shows, after three months, after non-
surgical periodontal treatment and according to the Brunner-Langer 
non-parametric model, as fundamental findings, the reduction of 
serum fibrinogen levels in the group treated with doxycycline 364.5 ± 
93.2 versus 347.0 ± 100.8 (p = 0.077), while in the control group the 
serum levels increased 314.8 ± 63.7 versus 320.4 ± 65.1 (p = 0.305). 
Plasma fibrinogen levels show, in our study, a positive correlation 
with the BOP index of probing bleeding at the limit of significance (p 
= 0.051), as an expression of the impact of local inflammation on the 
systemic inflammatory load. In the present study, our results can be 
interpreted by the presence of a residual inflammatory load, a result of 
the aggression caused by periodontal treatment, which would lead to an 
increase in acute phase reactants, including fibrinogen, and given the 
immunomodulatory properties of doxycycline, the final balance results 
in a decrease in the values of serum levels. On the other hand, in the 
present study, the levels of hsCRP remain unchanged 0.25 ± 0.22 versus 
0.22 ± 0.22 (p = 0.478), in the group treated with doxycycline, in line 
with other studies, which neither showed changes [37-39].
Conclusion
As a general conclusion of the present study, it can be stated that the 
effects on systemic proinflammatory markers remain undetermined at 
least in the short term. More studies with prospective and longitudinal 
characteristics, of greater size and duration, are necessary, in order 
to objectify with more precision the influence of periodontal disease 
with systemic inflammation and, consequently, its relationship with 
cardiovascular pathology. Moreover, treatment with doxycycline does 
not seem to have benefits on the improvement of serum levels of CRPus. 
Finally, and as a contribution to the present study, there is a decrease 
in serum fibrinogen levels after non-surgical periodontal treatment 
with the use of doxycycline as an adjuvant medication. This implies an 
important benefit, as a result of the reduction of the peaks of systemic 
inflammation, caused because of the periodontal treatment.
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